UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $43.70.

Several equities research analysts recently commented on URGN shares. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in URGN. China Universal Asset Management Co. Ltd. grew its position in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of UroGen Pharma during the 3rd quarter valued at $155,000. Verition Fund Management LLC bought a new stake in shares of UroGen Pharma during the 3rd quarter valued at $168,000. Finally, SG Americas Securities LLC purchased a new stake in shares of UroGen Pharma in the 3rd quarter worth $179,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Trading Down 2.2 %

NASDAQ:URGN opened at $10.52 on Tuesday. UroGen Pharma has a 52 week low of $10.26 and a 52 week high of $20.70. The stock has a market cap of $246.74 million, a price-to-earnings ratio of -3.34 and a beta of 1.06. The company’s 50 day moving average price is $11.84 and its 200-day moving average price is $13.71. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the prior year, the business posted ($0.68) earnings per share. On average, equities research analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.